

Claims

1. The use of an inhibitor of CSF-1 activity for the manufacture of a medicament for the treatment and/or prophylaxis of inflammatory bowel disease (IBD).
- 5 2. The use according to claim 1, wherein the inhibitor is a nucleic acid.
3. The use according to claim 1, wherein the inhibitor is a small molecule (NCE).
4. The use according to claim 1, wherein the inhibitor is an antibody or functionally active fragment or derivative thereof.
- 10 5. The use according to claim 4, wherein the antibody or fragment thereof is monoclonal, polyclonal, chimeric, humanised or bispecific.
6. The use according to claim 4 or claim 5 where the antibody fragment is a Fab, Fab', F(ab')₂, scFv or an epitope-binding fragment thereof.
7. The use according to any one of claims 4-6 wherein the antibody or fragment thereof is conjugated to one or more effector molecule(s).
- 15 8. The use according to any one of claims 4-7 in which the antibody or fragment thereof binds to CSF-1.
9. The use according to any one of claims 4-7 in which the antibody or fragment thereof binds to CSF-1R.
10. The use according to any one of claims 1-9 where the inflammatory bowel disease is 20 Crohn's disease.
11. The use according to any one of claims 1-9 where the inflammatory bowel disease is ulcerative colitis.
12. A method for the treatment and/or prophylaxis of inflammatory bowel disease (IBD) comprising administering a therapeutically effective amount of an inhibitor of CSF-1 25 activity.
13. The method according to claim 12, wherein the inhibitor is a nucleic acid.
14. The method according to claim 12, wherein the inhibitor is a small molecule (NCE).
15. The method according to claim 12, wherein the inhibitor is an antibody or a functionally active fragment or derivative thereof.
- 30 16. The method according to claim 15, wherein the antibody or fragment thereof is monoclonal, polyclonal, chimeric, humanised or bispecific.
17. The method according to claim 15 or claim 16 where the antibody fragment is a Fab, Fab', F(ab')₂, scFv or epitope binding fragment thereof.

18. The method according to any one of claims 15-17 wherein the antibody or fragment thereof is conjugated to one or more effector molecule(s).
19. The method according to any one of claims 15-18 in which the antibody or fragment thereof binds to CSF-1.
- 5 20. The method according to any one of claims 15-18 in which the antibody or fragment thereof binds to CSF-1R.
21. The method according to any one of claims 12-20 where the inflammatory bowel disease is Crohn's disease.
- 10 22. The method according to any one of claims 12-20 where the inflammatory bowel disease is ulcerative colitis.
23. The method according to any one of claims 12-22 where the inhibitor of CSF-1 activity is administered in combination with one or more other therapeutically active compounds.
- 15 24. The method according to claim 23 in which the other therapeutically active compound is another anti-IBD therapeutic agent.
25. The method according to claim 23 in which the other therapeutically active compound is an anti-cancer therapy.